This is an early phase (phase IIa), randomized, multi-center study in subjects with acute
lung injury (ALI) or acute respiratory distress syndrome (ARDS). The purpose of this study is
to investigate the safety of GSK2586881 and to determine what effects it has on people with
Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS).
The study has two parts: Part A will be an open-label investigation in five subjects. Part B
will be a double-blind, placebo controlled investigation and will involve approximately 60